Amgen (AMGN) News Today

Amgen Inc. (NASDAQ: AMGN) shares have increased as investors respond to favorable analyst actions and progress on a potential next-generation diabetes treatment.

• Positive Sentiment: UBS upgraded Amgen to Buy and raised its price target to $470 from $430, implying further upside from the reported $414.87 share price. The upgrade is the clearest near-term catalyst behind the stock’s strength. Benzinga analyst upgrade report
• Positive Sentiment: Amgen announced a head-to-head Phase 3 trial for its monthly diabetes drug candidate against semaglutide. Success could strengthen the company’s position in the highly competitive GLP-1 market and provide a significant future growth opportunity, although clinical and commercial risks remain. Amgen monthly diabetes trial article
• Positive Sentiment: Cantor Fitzgerald raised its Amgen price target to $440 from $400, signaling improved expectations despite maintaining a Hold rating. Cantor Fitzgerald price target report

• Neutral Sentiment: Cantor Fitzgerald and Morgan Stanley both maintained Hold ratings. While Cantor’s higher target is supportive, the Hold recommendations indicate that some analysts see limited risk-adjusted upside after Amgen’s substantial 12-month rally. Cantor Fitzgerald Hold rating
• Neutral Sentiment: A market report listed short interest at zero shares and a days-to-cover ratio of zero. If accurate, this suggests little reported short-selling pressure, though the figure appears inconsistent with the article’s description of an increase in short interest.

Amgen’s latest reported quarter also showed strong momentum, with revenue up 9.5% year over year and earnings exceeding consensus estimates. Investors are weighing that performance and the diabetes pipeline against valuation and the possibility that much of the near-term optimism is already reflected in the stock.